Table 3.
Kansas City Cardiomyopathy Questionnaire total symptom score, N-terminal pro-brain natriuretic peptide levels, fasting blood glucose, glycated hemoglobin, and body weight according to estimated glomerular filtration rate.
| Variables | EGFR | Baseline (n = 136) | 3 months’ follow-up (n = 127) | 6 months’ follow-up (n = 125) | 12 months’ follow-up (n = 124) |
|---|---|---|---|---|---|
| KCCQ total symptom score | <60 ml/min/1.73 m2 | 58.1 ± 24.0 | 68.1 ± 24.8 | 74.9 ± 27.1 | 79.5 ± 28.3 |
| EGFR ≥60 ml/min/1.73 m2 | 59.9 ± 24.3 | 69.7 ± 25.4 | 76.1 ± 27.8 | 79.9 ± 28.5 | |
| p-value | 0.187 | 0.201 | 0.198 | 0.298 | |
| NT-proBNP (pg/mL) | <60 ml/min/1.73 m2 | 949.5 ± 651.1 | 713.6 ± 547.9 | 598.6 ± 420.7 | 571.0 ± 318.9 |
| EGFR ≥60 ml/min/1.73 m2 | 989.1 ± 659.2 | 764.0 ± 563.4 | 623.2 ± 429.2 | 583.8 ± 326.2 | |
| p-value | 0.164 | 0.101 | 0.111 | 0.179 | |
| Fasting BG (mg/dL) | <60 ml/min/1.73 m2 | 156.4 ± 50.8 | 140.8 ± 42.4 | 122.5 ± 38.6 | 118.5 ± 33.5 |
| EGFR ≥60 ml/min/1.73 m2 | 153.4 ± 49.3 | 140.0 ± 42.0 | 120.5 ± 38.0 | 115.5 ± 32.8 | |
| p-value | 0.242 | 0.301 | 0.238 | 0.237 | |
| HbA1c (%) | <60 ml/min/1.73 m2 | 8.2 ± 1.5 | 7.4 ± 1.3 | 7.1 ± 1.1 | 6.9 ± 1.2 |
| EGFR ≥60 ml/min/1.73 m2 | 8.1 ± 1.4 | 7.2 ± 1.2 | 7.0 ± 1.1 | 6.7 ± 1.0 | |
| p-value | 0.302 | 0.289 | 0.311 | 0.291 | |
| Body weight (kg) | <60 ml/min/1.73 m2 | 96.8 ± 19.2 | 92.3 ± 16.4 | 86.6 ± 14.2 | 84.6 ± 13.1 |
| EGFR ≥60 ml/min/1.73 m2 | 98.8 ± 19.9 | 93.3 ± 16.8 | 87.6 ± 14.5 | 85.5 ± 13.2 | |
| p-value | 0.199 | 0.283 | 0.295 | 0.300 |
Continuous data are shown as means (standard deviations) and qualitative data as absolute value and percentages. Statistical significance was measured for the comparison of EGFR groups.
BG, blood glucose; EGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro-brain natriuretic peptide.